Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Amortization of Deferred Charges (2016 - 2025)

Altimmune (ALT) has disclosed Amortization of Deferred Charges for 9 consecutive years, with $113000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Amortization of Deferred Charges changed N/A to $113000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $173587.0, a N/A change, with the full-year FY2018 number at $180611.0, up 84.18% from a year prior.
  • Amortization of Deferred Charges was $113000.0 for Q3 2025 at Altimmune, up from $60587.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $113000.0 in Q3 2025 to a low of $113000.0 in Q3 2025.